Sponsors

Company Profile

Arteriocyte, Inc.

Gene/Cell Therapy
Cardiovascular Disease
Drug Development
Revascularization and Angiogenesis

11000 Cedar Avenue
Cleveland, OH 44106
USA
www.arteriocyte.com 		Incorporated in 2004
7 Employees 		Privately Held

This Year's Highlights

  • Company initiates Phase I clinical trial to evaluate the safety of adult derived hemangioblasts (stem cells) to treat chronic ischemia, a serious form of heart disease.
  • Company receives $600,000 Third Frontier Funding (State of Ohio) to Advance Development of Adult Stem Cell-Based Therapies

Anticipated Highlights

  • Company anticipates the completion of patient enrollment into its Phase I clinical trial by August, 2006.

Corporate Mission

Arteriocyte is a clinical stage research and development company focused on developing cellular therapies to treat ischemic disease. The company will capitalize on the bench to bedside expertise of its scientific founders to develop stem cell-based therapies for ischemic diseases with an initial focus on coronary applications. The clinical objective is "therapeutic angiogenesis" or the generation of new blood vessels to replace or supplement those blood vessels which no longer adequately supply a tissue. These cellular therapies will eventually help patients suffering from a number of ischemic conditions including coronary artery disease and peripheral vascular disease.